Vozmediano C, Rivera F, Lopez-Gomez JM, Hernandez D. Risk factors for renal failure in patients with lupus nephritis: data from the Spanish registry of glomerulonephritis. Nephron Extra 2012; 2(1): 269-77. doi: 10.1159/000342719.
Ebadi A, Zamani B, Soleimani AR, Tamadon MR, Arbabi M. Epidemiologic study of 40 patientswith lupus nephritis in Imam Khomeini. Bimonthly J Hormozgan Univ Med Sci 2006; 10(3): 231–6.
Saadati N, Haami M, BehroozAghdam A, Naghibzadeh B. Corrolation between clinical symptoms and renal pathology in patients with systemic lupus erythematosus (Persian). Med J Mashhad Univ Med Sci 55(2): 218-4.
Rajaee A, Behzadi S, Bazmi S, Moayeri M. The clinical and pathological findings among patients with lupus nephritis in Shiraz, Southern Iran. Shiraz E-Med J 2005; 6(1, 2): 2-7.
Barr RG, Seliger S, Appel GB, Zuniga R, D’Agati V,SalmonJ, et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Prognostic factors of lupus nephritis. Dial Transplant 2003; 18(10): 2039-46. doi: 10.1093/ndt/gfg345.
Hahn BH. Systemic Lupus Erythematosus. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, editors. Harrison’s principles of internal medicine. 18 ed. USA: Mc Graw Hill companies; 2012. p. 2732.
Dhir V, Aggarwal A, Lawrence A, Agarwal V, Misra R. Long-term outcome of lupus nephritis in Asian Indians. Arthritis Care Res (Hoboken) 2012; 64(5): 713-20. doi: 10.1002/acr.21597.
Yokoyama H, Wada T, Hara A, Yamahana J, Nakaya I, Kobayashi M, et al. The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int 2004; 66(6): 2382–8. doi: 10.1111/j.1523-1755.2004.66027.x.
Kotchen TA. Hypertensive vascular disease. In: Longo DL, Fauci AS, Kasper DL, Hauser S. L. editors. Harrison’s principles of internal medicine. 18 ed. USA: Mc Graw Hill companies; 2012. p. 2047.
Adamson JW, Longo DL. Anemia and Polycythemia. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, editors. Harrison’s principles of internal medicine. 18 ed. USA: Mc Graw Hill companies; 2012. p. 450.
Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000; 35(5): 904-14.
Bargman JM, Skorecki K. Chronic kidney disease. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, editors. Harrison’s principles of internal medicine. 18 ed. USA: Mc Graw Hill companies; 2012. p. 2308.
Lewis JB, Neilson EG. Glomerulardisease. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, editors. Harrison’s principles of internal medicine. 18 ed. USA: Mc Graw Hill companies; 2012. p. 2337.
Lin J, Denker BM. Azotemia and urinary abnormalities. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, editors. Harrison’s principles of internal medicine. USA: Mc Graw Hill companies; 2012. p. 339.
Tesar V, Hruskova Z. Treatment of proliferative lupus nephritis: a slowly changing landscape. Nat Rev Nephrol 2011; 7(2): 96-109. doi: 10.1038/nrneph.2010.170.
Nezhad ST, Sepaskhah R. Correlation of clinical and pathological findings in patients with lupus nephritis: a five-year experience in Iran. Saudi J Kidney Dis Transpl 2008; 19(1): 32-40.
Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ, Collaborative Study G. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008; 3(1): 46-53. doi: 10.2215/CJN.03280807.
Sircar D, Sircar G, Waikhom R, Raychowdhury A, Pandey R. Clinical features, epidemiology, and short-term outcomes of proliferative lupus nephritis in Eastern India. Indian J Nephrol 2013; 23(1): 5–11. doi: 10.4103/0971-4065.107187.
Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353(21): 2219-28. doi: 10.1056/NEJMoa043731.
Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis.Nephrol Dial Transplant 2007; 22(9): 2531-9. doi: 10.1093/ndt/ gfm245.
Miranda-Hernandez D, Cruz-Reyes C, Angeles U, Jara LJ, Saavedra MA. Prognostic factors for treatment response in patients with lupus nephritis. Reumatol Clin 2014; 10(3):164-9. doi: 10.1016/ j. reuma.2013.08.001.
Korbet SM, Schwartz MM, Evans J, Lewis EJ, Collaborative Study G. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007; 18(1): 244-54. doi: 10.1681/ASN. 2006090992.
Ghoreyshi FI. Prognosis in children with lupus nephritis. Med J Hormozgan Univ Med Sci 2005; 8(4): 193-7.
Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford) 2011; 50(8): 1424-30. doi: 10.1093/ rheumatology/ker101.
Kammoun K, Jarraya F, Bouhamed L, Kharrat M, Makni S, Hmida MB, et al. Poor prognostic factors of lupus nephritis. Saudi J Kidney Dis Transpl 2011; 22(4): 727-32.
Austin HA, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney International 1984; 25(4): 689-95. doi: 10.1038/ki.1984.75.
Birmingham DJ, Irshaid F, Nagaraja HN, Zou X, Tsao BP, Wu H, et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus 2010; 19(11): 1272–80. doi: 10.1177/0961203310371154.